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LDL particle size
Abstract
PRINCIPLES: Small dense LDLs have been found to be associated with type 2 diabetes (T2DM). This
association has been observed in the context of decreased HDL cholesterol and increased triglycerides.
METHODS: In the present study the relationship between LDL particle size and insulin sensitivity was
assessed in 46 patients with T2DM (mean age 60 (11) years, HbA1c 7.6 (0.8) %). 75 g oral glucose
tolerance testing was performed and composite insulin sensitivity index was calculated by the method of
Matsuda and de Fronzo (ISI(comp)). Additional parameters included BMI, waist circumference, blood
pressure, HDL cholesterol, triglycerides and LDL cholesterol. LDL particle size was measured by
gradient gel electrophoresis. RESULTS: Log ISI(comp) correlated most strongly with LDL particle size
(R = 0.61), less closely with HDL cholesterol (R = 0.48) and plasma triglycerides (R = -0.45) and not at
all with LDL cholesterol (R = 0.001), as supported by multiple regression analyses where log ISI(com)
was associated with LDL particle size (p = 0.004) and HDL cholesterol (p = 0.027) but not with
triglycerides and LDL cholesterol. CONCLUSION: Log ISI(comp) estimated by a formula using
endogenous insulin levels is very closely associated with LDL particle size in patients with T2DM. Our
data suggest that smaller LDL particle size reflects the impact of insulin resistance on lipoprotein
metabolism more strictly than do the traditional lipid parameters.
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Principles: Small dense LDLs have been found
to be associated with type 2 diabetes (T2DM).
This association has been observed in the context
of decreased HDL cholesterol and increased
triglycerides.
Methods: In the present study the relationship
between LDL particle size and insulin sensitivity
was assessed in 46 patients with T2DM (mean age
60 (11) years, HbA1c 7.6 (0.8) %). 75 g oral glu-
cose tolerance testing was performed and com-
posite insulin sensitivity index was calculated by
the method of Matsuda and de Fronzo (ISI(comp)).
Additional parameters included BMI, waist cir-
cumference, blood pressure, HDL cholesterol,
triglycerides and LDL cholesterol. LDL particle
size was measured by gradient gel electrophoresis. 
Results: Log ISI(comp) correlated most
strongly with LDL particle size (R = 0.61), less
closely with HDL cholesterol (R = 0.48) and
plasma triglycerides (R = –0.45) and not at all with
LDL cholesterol (R = 0.001), as supported by
multiple regression analyses where log ISI(com)
was associated with LDL particle size (p = 0.004)
and HDL cholesterol (p = 0.027) but not with
triglycerides and LDL cholesterol. 
Conclusion: Log ISI(comp) estimated by a for-
mula using endogenous insulin levels is very
closely associated with LDL particle size in pa-
tients with T2DM. Our data suggest that smaller
LDL particle size reflects the impact of insulin re-
sistance on lipoprotein metabolism more strictly
than do the traditional lipid parameters.
Key words: type 2 diabetes; insulin sensitivity;
LDL particle size; plasma triglycerides; HDL choles-
terol
Summary
The worldwide incidence of type 2 diabetes
mellitus is increasing and accounts for 6–12% of
total health care expenditure in industrialised
countries [1]. Hypertriglyceridaemia, low HDL
cholesterol and an increased fraction of small
dense LDL particles are frequent lipid abnormal-
ities in insulin resistance and type 2 diabetes mel-
litus [2–4], and are associated with increased car-
diovascular mortality [5, 6]. An association of
LDL particle size with the cluster of risk factors
that characterise the insulin resistance syndrome
has also been demonstrated [7] and there is strong
evidence that small dense LDL particles can be
added to the group of changes described as syn-
drome X, also termed the metabolic syndrome [3,
8, 9]. 
The aim of the present study was to investi-
gate the association of LDL particle size and of
traditional lipid parameters, particularly HDL
cholesterol and triglycerides with insulin sensitiv-
ity, in a cohort of patients with type 2 diabetes
mellitus.
Introduction
K. B. was supported
by an independent
basic research
grant from the
Swiss National
 Science Founda-
tion: 3200B0-
105258.
Methods
Patients were recruited from April 2001 to June
2002. Patients with type 2 diabetes treated by diet alone,
metformin or repaglinide at the Division of Endocrinol-
ogy, Diabetes and Clinical Nutrition and Medical Poli-
clinic of Zurich University Hospital were asked in the
routine medical consultation to participate in the study.
Exclusion criteria were symptomatic CHD, autonomic
neuropathy and treatment with insulin or insulin sensitis-
ing agents. 46 patients who agreed to participate in the
study were enrolled and all of them were included in the
2008;138(19-20):275–280
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final analysis. Written informed consent was obtained
and the study was approved by the local medical ethics
committee.
All patients were interviewed during the visit. Infor-
mation was collected on the duration of diabetes, hyper-
tension, smoking habits and current treatment. Patients
on sulfonylurea were changed to repaglinide two weeks
before sampling. Overnight fasting blood samples were
drawn while the subjects remained in a sitting position
and blood was centrifuged within 30 min. Plasma for
analysis for LDL particle size was frozen at –80 °C until
further analysis. Total cholesterol, LDL cholesterol,
HDL cholesterol, triglycerides, ALT, uric acid and hs-
CRP were determined at Zurich University Hospital In-
stitute for Clinical Chemistry. Total cholesterol, HDL
cholesterol, triglycerides, ALT and uric acid, were
analysed on a Roche Modular Analytics System using
commercial assays from Roche Diagnostics (Rotkreuz,
Switzerland) with a maximum inter-assay variation of
2.3%, 6.8%, 4.2%, 5.7%, and 3.1%, respectively. LDL
cholesterol was calculated according to the formula of
Friedewald [10]. Hs-CRP was determined on an Im-
mulite 2000 chemiluminescence analyser using commer-
cial reagents from Diagnostic Products Corporation (Los
Angeles, USA) with a maximum inter-assay variation of
6.3% and a detection limit of 0.1 mg/L. 
A standard oral glucose tolerance test was performed
with a 75 g glucose load after an overnight fast. In the
morning an intravenous catheter was inserted into an an-
tecubital vein. Blood samples were obtained at baseline
(mean of two samples) and 30, 60, 90, and 120 min after
the glucose load. 
Venous blood samples were drawn into sodium fluo-
ride-containing tubes for determination of plasma glu-
cose. Plasma glucose was measured by the glucose oxi-
dase technique (Beckman Analyzer; Beckman, Fullerton,
CA, USA). Insulin was measured in serum samples by
solid phase radioimmunoassay (CIS Bio international,
Oris Industries, Gif-Sur-Yvette, France) with a cross-
reactivity of 14% for proinsulin and 0.1% for C-pep-
tide; normal overnight fasting range stated by the manu-
facturer was 30 to 138 pmol/L; lower limit of detec-
tion 14 pmol/L. HbA1c was measured by DCA 2000
(Bayer Diagnostics, Zurich, Switzerland). Composite 
insulin sensitivity index [ISI(comp)] was calculated by 
the method of Matsuda and DeFronzo using the 75 g 
OGTT [11]: ISI(comp) = 10000 / square root of
Gluc0(mg/dl)xIns0(mU/L)xGlucMean(mg/dl)xInsMean(mU/
L). HOMA-IR was calculated as proposed by Matthews
[12]: Ins0(mU/l)xGluc0(mmol/l)/22.5. Insulinogenic
index was calculated as proposed by Wareham [13] as the
ratio of the increment of plasma insulin to plasma glucose
at 30 min after the glucose load: Ins30(pmol/L)-
Ins0(pmol/L)/Gluc30(mmol/l). Inst and Gluct represent
the insulin and glucose concentrations at time t during
the OGTT. Insmean and Glucmean represent the mean in-
sulin and glucose concentrations during the OGTT.
Nondenaturing polyacrylamide gradient gel elec-
trophoresis (GGE) of plasma was performed at 10–14 °C
in 2–16% polyacrylamide gradient gels. Gels were sub-
jected to electrophoresis for 24 h at 125 V in tris borate
buffer (pH 8.3) as described elsewhere [14, 15]. Gels were
fixed and stained for lipids in a solution containing oil red
O in 60% ethanol at 55 °C. Gels were placed on a light
source and photographed with a Canon G3 digital cam-
era. Migration distance for each absorbance peak was de-
termined and the molecular diameter corresponding to
each peak was calculated from a calibration curve gener-
ated from the migration distance of size standards of
known diameter, which includes carboxylated latex beads
(Duke Scientific, Palo Alto, CA), thyroglobulin and apo-
ferritin (HMW Std, Pharmacia, Piscataway, NJ) having a
molecular diameter of 380 Å, 170 Å and 122 Å, respec-
tively, and lipoprotein calibrators of previously deter-
mined particle size.
Statistical analysis
Data are presented as means with standard devia-
tions or medians with interquartile ranges. Evaluations
were performed using Statistica version 6 and SPSS ver-
sion 14.0. Bivariate correlation coëfficients R mean Pear-
son’s parametric calculations. Multiple regression analy-
ses were performed on LDL particle size, HDL choles-
terol, triglycerides and LDL cholesterol, taking patient
characteristics and baseline data as independent variables.
Highly skewed values were normalised by logarithmic
transformation. A stepwise backward elimination proce-
dure was chosen with p 00.10 as exclusion criterion lead-
ing to the final models presented with 2–6 variables. Oc-
currence of collinearity was resolved by exclusion of cor-
related variables. P-values <0.05 were considered statisti-
cally significant.
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Results
Subject characteristics
46 patients (33 men and 13 women) with type
2 diabetes were included in the study and under-
went oral glucose challenge. Baseline characteris-
tics of the patients are shown in table 1. Average
duration of diabetes was 7.2 (SD 6.6) years and
HbA1c 7.6 (0.8) % at recruitment. Glucose lower-
ing therapy consisted of diet only in 13 (28%) pa-
tients ; 18 patients (39%) were treated with either
repaglinide or metformin and 15 patients (33%)
with both agents. 42 patients (91%) had a BMI
over 25 kg/m2 with a mean of 30 (4) kg/m2 in the
study population. Waist circumference was 094
cm in 29 of the 33 men and 080 cm in 12 of the 13
women, with a mean of 104 (10) cm. 34 (74%) had
blood pressure 0130/80 mm Hg or were treated
with antihypertensive drugs. 6 (13%) patients
were on statin therapy and 8 (17%) patients were
smokers. Fasting, 2 h-postload plasma glucose, in-
dices determined during the OGTT, LDL parti-
cle size, lipid parameters and other laboratory
data are shown in table 1.
Correlation of LDL particle size, HDL
 cholesterol, triglycerides and LDL cholesterol
with indices of insulin sensitivity
Figure 1 shows the correlation of LDL parti-
cle size and the traditional lipid parameters with
both indices of insulin sensitivity. Of the four 
lip id parameters, LDL particle size showed the
strongest correlation with log ISI(comp) (R =
0.61, p <0.001) and log HOMA-IR (R = –0.53, p =
0.001). A weaker but still significant correlation
was found for HDL cholesterol and triglycerides
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with both indices. On the other hand, there was
no correlation between LDL cholesterol and log
ISI(comp) and log HOMA.
The relations of log ISI(comp) with LDL
particle size and the three traditional lipid para -
meters of figure 1 were tested for significance by
multiple regression analysis, including patient
characteristics and baseline parameters (table 2).
Log ISI(comp) remained significantly associated
with LDL particle size (p = 0.004) and HDL cho-
lesterol (p = 0.027), but not with triglycerides and
LDL cholesterol.
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Discussion
In the present study correlation analysis sug-
gested, and multiple regression analysis afforded
evidence, that LDL particle size in type 2 diabetes
was by far the strongest marker of insulin sensitiv-
ity and stronger than traditional lipid parameters.
To the best of our knowledge this is the first time
this association has been clearly shown, (1) within
a group of patients with type 2 diabetes, (2) using
indices derived from endogenous insulin values
(thus more closely addressing the importance of
insulin sensitivity at ambient insulin levels than
does the hyperinsulinaemic clamp method and
preferentially addressing insulin sensitivity in
skeletal muscle), and (3) using the sensitive lipid
gel methodology. 
It is well known that hypertriglyceridaemia,
low HDL cholesterol and decreased LDL particle
size are frequent lipid abnormalities in insulin re-
sistance and type 2 diabetes mellitus [2–4, 20–24]
and are associated with an increased risk of cardio-
vascular disease [5, 16–18]. In addition, an associa-
tion of LDL particle size with the cluster of risk
factors that characterise insulin resistance and the
metabolic syndrome has also been demonstrated
[7, 9], while there is strong evidence that the
smaller denser LDL particles can be added to the
group of changes described as syndrome X or
metabolic syndrome [3, 8]. The present study
 suggests that determination of two standard key
markers of diabetic dyslipidaemia – plasma
triglycerides and HDL cholesterol – does not
necessarily replace the analysis of apo-B-
containing atherogenic particles such as small
dense LDL. One reason for this finding may be
that LDL size remains relatively stable over time,
in contrast to plasma triglycerides which exhibit
more marked alterations depending on the pran-
dial state.
To avoid confounding by hyperglycaemia, the
relationship between insulin resistance and
lipoproteins has often been studied in normal sub-
jects. However, the issue may be more complex
but equally relevant in patients with type 2 dia-
betes; in the latter condition there may be not
only impaired clearance of LDLs but also in-
creased, hyperglycaemia-driven hepatic output of
triglyceride-rich VLDL,1 as suggested in a study
using stable isotopes [19].
In morbidly obese women with normo -
glycaemia, impaired glucose tolerance (IGT) 
and non-insulin-dependent diabetes mellitus
(NIDDM) Barakat et al. found a decrease in
plasma insulin and triglyceride levels and an in-
crease in LDL size following gastric bypass sur-
gery, while cholesterol and LDL cholesterol levels
remained unchanged [20]. Haffner et al. have
shown that LDL particle size is correlated with
impaired glucose tolerance in non-diabetic sub-
jects [21]. Importantly, Reaven and colleagues
Patients with type 2
diabetes 
(n = 46)
Age, y 60 (11)
Male gender, % 72
Body mass index, kg/m2 30 (4)
Waist circumference, cm 104 (10)
Arterial hypertension, % 74
Smoking, % 17
Diabetes duration, y 7.2 (6.6)
Repaglinide therapy, % 46
Metformin therapy, % 59
Statin treatment, % 13
Laboratory data
Haemoglobin A1c, % 7.6 (0.8)
Fasting plasma glucose, mmol/l 8.7 (2.2)
2-h-postload plasma glucose, mmol/l 16.2 (3.2)
Insulin sensitivity index* 1.7 (1.3–2.7)
HOMA-IR† 7.9 (5.2–6.8)
Insulinogenic index‡ 6.9 (3.5–14)
ALT, U/L 24 (16–34)
Uric acid, mmol/L 344 (287–391)
Hs-CRP, mg/L 2.6 (1.4–7.2)
LDL particle size, Å 266 (9)
HDL cholesterol, mmol/L 1.4 (0.4)
LDL cholesterol, mmol/L 3.5 (0.9)
Triglycerides, mmol/L 1.5 (0.8)
Values are % of patients, means with SD or medians with
interquartile range. 
* Composite insulin sensitivity index [ISI(comp)] was calculated as
proposed by Matsuda and DeFronzo [11]
10 000 / square root of Gluc0(mg/dl)xIns0(mU/L) x
GlucMean(mg/dl)xInsMean(mU/L).
† HOMA-IR was calculated as proposed by Matthews [12]:
Ins0(mU/L)xGluc0(mmol/l)/22.5. 
‡ Insulinogenic index was calculated as proposed by Wareham
[13] Ins30(pmol/L)-Ins0(pmol/L)/Gluc30(mmol/l).
Inst and Gluct represent the insulin and glucose concentrations at
time t during the OGTT. Insmean and Glucmean represent the mean
insulin and glucose concentrations during the OGTT.
Table 1
Demographic, clinical
and laboratory base-
line data of 46 pa-
tients with type 2
 diabetes. 
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have demonstrated that among 100 normal
adults, those with pattern B (predominance of
small dense LDL particles)  were more insulin re-
sistant than those with pattern A, as judged by an
oral glucose challenge, and that this relationship
persisted even when differences in gender, age
and the degree of obesity were taken into consid-
eration [22]. On the basis of these data it has been
suggested that the pattern B phenotype may re-
flect insulin resistance. Using nuclear magnetic
resonance and hyperinsulinaemic clamps to com-
pare insulin sensitive, insulin resistant individuals
and untreated patients with type 2 diabetes it has
been shown that insulin resistance was associated
with an increase in VLDL size and a decrease in
LDL particle size. However, no multivariate
analysis to test whether the associations between
altered lipoprotein sizes and insulin resistance are
independent of the traditional lipid parameters
within the group of patients with type 2 diabetes,
such as HDL cholesterol and triglycerides, was
reported in this paper [23] and, to the best of our
knowledge, has not been so far. A strong inverse
relationship between LDL particle size and
triglycerides has been demonstrated in the litera-
ture, as summarised in [17]. Festa and colleagues
demonstrated an inverse relation of LDL particle
size and proinsulin concentrations, but in a het-
erogeneous population [24]. The studies sum-
marised above and our present data are in con-
trast to a study by Lahdenpera et al., who, using
euglycaemic clamping, found no difference in
lipid, lipoprotein concentrations and LDL parti-
cle size distribution between the more insulin re-
278Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size
Figure 1
Correlation analysis
of LDL particle size,
plasma HDL choles-
terol, plasma triglyc-
erides and LDL cho-
lesterol with log
ISI(comp) and log
HOMA, respectively.
Correlation analyses
were done using
Pearson’s correlation.
For calculations and
abbreviations of log
ISI(comp) and log
HOMA see footnote
table 1.
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sistant and less insulin resistant subjects [25]. In
their study LDL particle size was not associated
with insulin-stimulated glucose uptake and serum
insulin. The reason for these contrasting findings
is unclear. Our data suggest that smaller LDL
particle size reflects the impact of insulin resis -
tance on lipoprotein metabolism more strictly
than do the traditional lipid parameters. However,
these associations cannot be interpreted as causal
relationships. 
There are a number of potentially confound-
ing factors in the present study. Six subjects were
under treatment with statins. Hypolipidaemic
treatment with statins may result in a shift to larger
LDL particles [26, 27]. Thus, these patients may
have had even smaller LDL particles before initia-
tion of hypolipidaemic treatment. Thirty-three pa-
tients were male and thirteen female. It is known
that LDL particle size in women is larger than in
men. However, antidiabetic therapy and gender were
included in the multivariate regression analysis and
did not remain in the final model for LDL particle
size. Taken together, our data show that determina-
tion of LDL particle size provides information on
the dyslipidaemic pattern characteristic of type 2 di-
abetes beyond that provided by measuring triglyc-
erides and HDL cholesterol. Insulin resistance was
most closely reflected by lower LDL particle size,
which may not only represent an excellent marker
but possibly also a mediator of the cardiovascular
harm associated with insulin resistance in patients
with type 2 diabetes. 
We thank Susanne Vosmeer, Kaethy Dembinski,
Heidi Seiler and Cornelia Zwimpfer for their excellent
technical support. We thank Dr. G. Hinz, MEDIDATA
Zurich, for assistance in statistical analysis.
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Dependent Independent var. Regression 95% CI Regression Signif. Partial R2
variable (final model) coeff. B of B coeff. Beta (p-value) correlation (adjusted)
LDL particle size ISI comp (log) 7.3 2.4–12.1 0.347 0.004 0.42 0.56
Triglycerides (log) –9.4 -13.5–5.3 –0.526 <0.001 –0.57
HDL cholesterol Gender –0.29 -0.44 – -0.15 –0.479 <0.001 –0.55 0.62
(log) Statin treatment 0.22 0.05–0.38 0.269 0.010 0.40
lSI comp (log) 0.16 0.02–0.29 0.251 0.027 0.34
Triglycerides (log) –0.22 -0.35 – -0.09 –0.423 0.001 –0.48
LDL-chol. 0.11 0.04–0.17 0.351 0.003 0.46
hs-CRP (log) –0.07 -0.13 – -0.02 –0.305 0.008 –0.41
Triglycerides HDL-chol. (log) –0.73 -1.15 – -0.31 –0.386 0.001 –0.48 0.62
(log) LDL-chol. 0.20 0.09–0.31 0.350 0.001 0.48
LDL particle size –0.03 -0.04 – -0.02 –0.486 <0.001 –0.57
LDL cholesterol Statin treatment –0.83 -1.49 – -0.17 –0.305 0.015 –0.36 0.38
HDL-chol. (log) 1.95 1.02–2.88 0.582 <0.001 0.55
Triglycerides (log) 1.18 0.68–1.68 0.667 <0.001 0.59
CI: confidence interval; Beta: standardised regression coefficient. R2:coefficient of determination
Table 2
Multiple stepwise
backward regressions
on LDL particle size,
HDL cholesterol,
triglycerides, LDL
cholesterol with log
ISI(comp) and demo-
graphic and labora-
tory data of 46 pa-
tients with type 2
 diabetes.
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